KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses (2016 - 2020)

Regeneron Pharmaceuticals (REGN) has disclosed Other Accumulated Expenses for 10 consecutive years, with $122.4 million as the latest value for Q4 2020.

  • For Q4 2020, Other Accumulated Expenses rose 44.0% year-over-year to $122.4 million; the TTM value through Dec 2020 reached $122.4 million, up 44.0%, while the annual FY2020 figure was $122.4 million, 44.0% up from the prior year.
  • Other Accumulated Expenses hit $122.4 million in Q4 2020 for Regeneron Pharmaceuticals, up from $96.9 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $122.4 million in Q4 2020 and bottomed at $267000.0 in Q4 2017.
  • Average Other Accumulated Expenses over 4 years is $39.8 million, with a median of $3.7 million recorded in 2016.
  • Year-over-year, Other Accumulated Expenses soared 518.22% in 2016 and then plummeted 93.51% in 2017.
  • Regeneron Pharmaceuticals' Other Accumulated Expenses stood at $1.2 million in 2016, then plummeted by 77.33% to $267000.0 in 2017, then soared by 31735.21% to $85.0 million in 2019, then soared by 44.0% to $122.4 million in 2020.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $122.4 million, $96.9 million, and $103.8 million for Q4 2020, Q3 2020, and Q2 2020 respectively.